Tags

Type your tag names separated by a space and hit enter

Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disorders.
Gen Pharmacol. 1990; 21(6):821-5.GP

Abstract

1. The evidence reviewed here indicates that pinaverium bromide (Dicetel) relaxes gastrointestinal (GI) structures primarily by inhibiting Ca2+ influx through potential-dependent channels of surface membranes of smooth muscle cells. 2. The in vivo selectivity of pinaverium bromide for the GI tract appears to be due mainly to its pharmacokinetic properties. Because of its low absorption (typical for quaternary ammonium compounds) and marked hepatobiliary excretion, most of the orally-administered dose of pinaverium bromide remains in the GI tract. 3. Orally-administered pinaverium bromide does not elicit adverse cardiovascular side-effects at doses that effectively relieve GI spasm, pain, transit disturbances and other symptoms related to motility disorders. 4. Pinaverium bromide is the only Ca2(+)-antagonist with known therapeutic efficacy in the treatment of irritable bowel syndrome and certain other functional intestinal disorders.

Authors+Show Affiliations

R&D Department, Laboratoires de Thérapeutique Moderne, Suresnes, France.

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

2177709

Citation

Christen, M O.. "Action of Pinaverium Bromide, a Calcium-antagonist, On Gastrointestinal Motility Disorders." General Pharmacology, vol. 21, no. 6, 1990, pp. 821-5.
Christen MO. Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disorders. Gen Pharmacol. 1990;21(6):821-5.
Christen, M. O. (1990). Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disorders. General Pharmacology, 21(6), 821-5.
Christen MO. Action of Pinaverium Bromide, a Calcium-antagonist, On Gastrointestinal Motility Disorders. Gen Pharmacol. 1990;21(6):821-5. PubMed PMID: 2177709.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disorders. A1 - Christen,M O, PY - 1990/1/1/pubmed PY - 1990/1/1/medline PY - 1990/1/1/entrez SP - 821 EP - 5 JF - General pharmacology JO - Gen Pharmacol VL - 21 IS - 6 N2 - 1. The evidence reviewed here indicates that pinaverium bromide (Dicetel) relaxes gastrointestinal (GI) structures primarily by inhibiting Ca2+ influx through potential-dependent channels of surface membranes of smooth muscle cells. 2. The in vivo selectivity of pinaverium bromide for the GI tract appears to be due mainly to its pharmacokinetic properties. Because of its low absorption (typical for quaternary ammonium compounds) and marked hepatobiliary excretion, most of the orally-administered dose of pinaverium bromide remains in the GI tract. 3. Orally-administered pinaverium bromide does not elicit adverse cardiovascular side-effects at doses that effectively relieve GI spasm, pain, transit disturbances and other symptoms related to motility disorders. 4. Pinaverium bromide is the only Ca2(+)-antagonist with known therapeutic efficacy in the treatment of irritable bowel syndrome and certain other functional intestinal disorders. SN - 0306-3623 UR - https://www.unboundmedicine.com/medline/citation/2177709/Action_of_pinaverium_bromide_a_calcium_antagonist_on_gastrointestinal_motility_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0306-3623(90)90439-S DB - PRIME DP - Unbound Medicine ER -